vTv Therapeutics Inc. (Class A) (VTVT) Next Earnings Date & Expected ±10.9% Move

The Roarable RQD rating assigns a score of 33 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of -24.21%. For a prospective investor, these figures indicate that the business is consuming capital rather than generating it, so upside depends on future cash generation that the source data does not show.
• Whale 13F Flow: 10 / 20. The pillar description references institutional accumulation and options positioning. The holders section contains no detail, so the specific flow pattern cannot be verified from source data.
• Insider Conviction: 3 / 20. The pillar description references SEC Form 4 and Congressional PTR cluster flow. The holders section is empty, so no insider transactions can be confirmed. The low score indicates weak insider conviction signals.
• Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move in line with the market, which offers no defensive cushion in a downturn.
• Forensic Balance Sheet: 7 / 20. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. These readings point to elevated financial distress risk and weak fundamental quality.

Taken together, the rating signals that the stock carries substantial forensic and fundamental risk. A prospective investor evaluating the stock today would weigh the potential for a rebound against a cash-burning profile, weak forensic scores, and limited verified insider or analyst support.

Per the SEC financials, the company reported operating and net losses across all three periods, with margins at 0% on the market data sheet. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 0.2, and the Piotroski F-Score is 2/9, indicating weak profitability and balance-sheet strength. Cash rose from $36.7M to $88.9M between FY 2024 and FY 2025 per the SEC financials, while debt is listed as N/A in all periods, so the balance sheet posture cannot be fully assessed from the source data beyond the Debt/Equity ratio of 0.5 noted in the Roarable RQD rating.

• CATALYST (GREEN): A headline reports the stock jumped on FDA orphan drug status (per Yahoo Finance headline). The article body is not in source data, so the regulatory details are unverified.
• MARKET WIRE (YELLOW): Simply Wall St, MarketBeat (a "Buy" rating at BTIG Research), and Stock Titan items are listed. The MarketBeat items include a downgrade to Sell by Wall Street Zen. Mixed analyst signals appear in these headlines.
• RISK WATCH (RED): A headline reports the stock fell 3.81% to $26.54 and approached support at $25.21. The source attribution in this item is inconsistent, so its reliability is limited.
• The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. A prospective investor should note that the absence of mapped links means no verified ripple effects can be drawn from this dataset.

• What specific products or drug candidates generate the company's business, and what is the revenue model behind the $1.0M in FY 2024 revenue?
• What is the debt structure, given that debt is listed as N/A in all periods while Debt/Equity is cited as 0.5?
• What are the P/E, EPS, and EV/EBITDA figures, which are absent from the source data for a loss-making company?
• Does the FDA orphan drug status referenced in the news wire have verified regulatory documentation behind it?
• Who are the institutional holders, insiders, and any congressional traders, given that the holders section is empty?